JP4676960B2 - 第Ｘａ因子阻害剤としてのインドール誘導体 - Google Patents

第Ｘａ因子阻害剤としてのインドール誘導体 Download PDF

Info

Publication number
JP4676960B2
JP4676960B2 JP2006529740A JP2006529740A JP4676960B2 JP 4676960 B2 JP4676960 B2 JP 4676960B2 JP 2006529740 A JP2006529740 A JP 2006529740A JP 2006529740 A JP2006529740 A JP 2006529740A JP 4676960 B2 JP4676960 B2 JP 4676960B2
Authority
JP
Japan
Prior art keywords
alkyl
indole
unsubstituted
alkylene
mono
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006529740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006528940A5 (https=
JP2006528940A (ja
Inventor
マルク・ナザレ
フォルクマール・ヴェーナー
クルト・リッター
フォルカー・ラウクス
Original Assignee
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング filed Critical サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング
Publication of JP2006528940A publication Critical patent/JP2006528940A/ja
Publication of JP2006528940A5 publication Critical patent/JP2006528940A5/ja
Application granted granted Critical
Publication of JP4676960B2 publication Critical patent/JP4676960B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2006529740A 2003-05-19 2004-05-05 第Ｘａ因子阻害剤としてのインドール誘導体 Expired - Fee Related JP4676960B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03011306A EP1479677A1 (en) 2003-05-19 2003-05-19 New indole derivatives as factor xa inhibitors
PCT/EP2004/004751 WO2004101554A1 (en) 2003-05-19 2004-05-05 New indole derivatives as factor xa inhibitors

Publications (3)

Publication Number Publication Date
JP2006528940A JP2006528940A (ja) 2006-12-28
JP2006528940A5 JP2006528940A5 (https=) 2007-06-21
JP4676960B2 true JP4676960B2 (ja) 2011-04-27

Family

ID=33040953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006529740A Expired - Fee Related JP4676960B2 (ja) 2003-05-19 2004-05-05 第Ｘａ因子阻害剤としてのインドール誘導体

Country Status (15)

Country Link
US (1) US7196103B2 (https=)
EP (2) EP1479677A1 (https=)
JP (1) JP4676960B2 (https=)
AT (1) ATE475659T1 (https=)
AU (1) AU2004238495B2 (https=)
BR (1) BRPI0410466A (https=)
CA (1) CA2526066A1 (https=)
CL (1) CL2004001074A1 (https=)
DE (1) DE602004028367D1 (https=)
MX (1) MXPA05012232A (https=)
PA (1) PA8603601A1 (https=)
PE (1) PE20050156A1 (https=)
TW (1) TW200510393A (https=)
UY (1) UY28325A1 (https=)
WO (1) WO2004101554A1 (https=)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) * 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7741341B2 (en) 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
US7317027B2 (en) * 2003-05-19 2008-01-08 Sanofi-Aventis Deutschland Gmbh Azaindole-derivatives as factor Xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
EP1571154A1 (en) * 2004-03-03 2005-09-07 Aventis Pharma Deutschland GmbH Beta-aminoacid-derivatives as factor Xa inhibitors
FR2888847B1 (fr) * 2005-07-22 2007-08-31 Sanofi Aventis Sa Derives de n-(heteriaryl)-1-heteorarylalkyl-1h-indole-2- carboxamides, leur preparation et application en therapeutique
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
SI3095447T1 (sl) 2006-02-03 2022-02-28 Opko Renal, Llc Zdravljenje pomanjkanja vitamina D s 25-hidroksivitaminom D2 in 25-hidroksivitaminom D3
HUE037309T2 (hu) 2006-06-21 2018-08-28 Opko Ireland Global Holdings Ltd Terápia D-vitamin telítési szer alkalmazásával és D-vitamin hormon helyettesítõ szer
PL2148661T3 (pl) 2007-04-25 2013-07-31 Cytochroma Inc Doustne kompozycje o kontrolowanym uwalnianiu zawierające związek będący witaminą D i woskowy nośnik
PT3335712T (pt) 2007-04-25 2025-10-23 Opko Renal Llc Método de tratamento e prevenção seguro e eficaz do hiperparatiroidismo secundário na doença renal crónica
TW200920369A (en) 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
US8716308B2 (en) 2008-01-11 2014-05-06 Albany Molecular Research, Inc. (1-azinone)-substituted pyridoindoles
CN102046812A (zh) 2008-04-02 2011-05-04 赛特克罗公司 用于维生素d缺乏症和相关障碍的方法、组合物、用途和试剂盒
JP5791500B2 (ja) 2008-05-23 2015-10-07 パンミラ ファーマシューティカルズ，エルエルシー． ５−リポキシゲナーゼ活性化タンパク質阻害剤
US8546431B2 (en) 2008-10-01 2013-10-01 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
NZ624963A (en) 2009-04-29 2016-07-29 Amarin Pharmaceuticals Ie Ltd Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
US8637501B2 (en) * 2009-07-01 2014-01-28 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine MCH-1 antagonists, methods of making, and use thereof
US9073925B2 (en) * 2009-07-01 2015-07-07 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) * 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
US8629158B2 (en) * 2009-07-01 2014-01-14 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine MCH-1 antagonists, methods of making, and use thereof
PT2552484T (pt) 2010-03-29 2020-04-03 Opko Ireland Global Holdings Ltd Métodos e composições para redução dos níveis de parafróides
WO2012088038A2 (en) 2010-12-21 2012-06-28 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline mch-1 antagonists, methods of making, and uses thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
KR101847947B1 (ko) 2013-03-15 2018-05-28 옵코 아이피 홀딩스 Ⅱ 인코포레이티드 안정화되고 변형된 비타민 ｄ 방출 제형
US10220047B2 (en) 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
MY198547A (en) 2016-03-28 2023-09-04 Opko Ireland Global Holdings Ltd Methods of vitamin d treatment

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11469A (en) * 1854-08-08 boynton
US4675332A (en) * 1984-12-10 1987-06-23 Warner-Lambert Company Acidic tetrazolyl substituted indole compounds and their use as antiallergy agents
JPH0287282A (ja) * 1988-09-22 1990-03-28 Nec Corp グラフ作図レイアウト決定方式
US5506134A (en) 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5788965A (en) 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
TW229140B (https=) * 1992-06-05 1994-09-01 Shell Internat Res Schappej B V
SI9520044B (sl) 1994-04-26 2004-08-31 Aventis Pharmaceuticals Inc. Inhibitorji Xa faktorja
US20040043995A1 (en) * 1997-05-13 2004-03-04 Eric Bignon Novel triazole derivatives, process for their preparation and pharmaceutical compositions containing them
FR2763337B1 (fr) * 1997-05-13 1999-08-20 Sanofi Sa Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
HU227568B1 (en) * 1997-12-24 2011-08-29 Sanofi Aventis Deutschland Indole derivatives, as inhibitors os factor xa
WO2000007591A1 (en) * 1998-08-03 2000-02-17 Eli Lilly And Company INDOLE sPLA2 INHIBITORS
EP0987274A1 (en) * 1998-09-15 2000-03-22 Hoechst Marion Roussel Deutschland GmbH Factor VIIa Inhibitors
US6486211B1 (en) * 1999-10-22 2002-11-26 Smithkline Beecham Corporation Indole compounds
US7053070B2 (en) * 2000-01-25 2006-05-30 Warner-Lambert Company Pyrido[2,3-d]pyrimidine-2,7-diamine kinase inhibitors
US6436965B1 (en) * 2000-03-02 2002-08-20 Merck Frosst Canada & Co. PDE IV inhibiting amides, compositions and methods of treatment
HUP0302397A3 (en) * 2000-05-26 2007-02-28 Nippon Shinyaku Co Ltd Heterocyclic compounds and pharmaceutical compositions containing them
NZ522074A (en) * 2000-05-31 2004-06-25 Astrazeneca Ab Indole derivatives with vascular damaging activity
US20030165837A1 (en) * 2000-06-14 2003-09-04 The Scripps Research Institute Method for screening DNA binding
WO2001096313A1 (en) * 2000-06-14 2001-12-20 The Scripps Research Institute Distamycin a analogs
US6525202B2 (en) * 2000-07-17 2003-02-25 Wyeth Cyclic amine phenyl beta-3 adrenergic receptor agonists
EP1217000A1 (en) * 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
DE10147672A1 (de) * 2001-09-27 2003-04-10 Bayer Ag Substituierte 2,5-Diamidoindole und ihre Verwendung
US7064135B2 (en) * 2001-10-12 2006-06-20 Novo Nordisk Inc. Substituted piperidines
EP1314733A1 (en) * 2001-11-22 2003-05-28 Aventis Pharma Deutschland GmbH Indole-2-carboxamides as factor Xa inhibitors
US7358268B2 (en) * 2002-12-04 2008-04-15 Sanofi-Aventis Deutschland Gmbh Imidazole derivatives as factor Xa inhibitors
US7429581B2 (en) 2002-12-23 2008-09-30 Sanofi-Aventis Deutschland Gmbh Pyrazole-derivatives as factor Xa inhibitors
US7078419B2 (en) * 2003-03-10 2006-07-18 Boehringer Ingelheim Pharmaceuticals, Inc. Cytokine inhibitors
US7049323B2 (en) * 2003-04-25 2006-05-23 Bristol-Myers Squibb Company Amidoheterocycles as modulators of the melanocortin-4 receptor
EP1479675A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Indazole-derivatives as factor Xa inhibitors
US7741341B2 (en) * 2003-05-19 2010-06-22 Sanofi-Aventis Deutschland Gmbh Benzimidazole-derivatives as factor Xa inhibitors
EP1479677A1 (en) 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH New indole derivatives as factor xa inhibitors
US7223780B2 (en) * 2003-05-19 2007-05-29 Sanofi-Aventis Deutschland Gmbh Triazole-derivatives as blood clotting enzyme factor Xa inhibitors
US7405670B2 (en) * 2005-07-29 2008-07-29 Fitzgerald Timothy W Method and system for detecting and isolating stray voltage

Also Published As

Publication number Publication date
EP1633746B1 (en) 2010-07-28
CL2004001074A1 (es) 2005-03-28
BRPI0410466A (pt) 2006-05-30
AU2004238495B2 (en) 2010-07-22
MXPA05012232A (es) 2006-08-18
US7196103B2 (en) 2007-03-27
EP1479677A1 (en) 2004-11-24
TW200510393A (en) 2005-03-16
UY28325A1 (es) 2004-12-31
US20050033049A1 (en) 2005-02-10
WO2004101554A1 (en) 2004-11-25
DE602004028367D1 (de) 2010-09-09
EP1633746A1 (en) 2006-03-15
JP2006528940A (ja) 2006-12-28
CA2526066A1 (en) 2004-11-25
ATE475659T1 (de) 2010-08-15
AU2004238495A1 (en) 2004-11-25
PE20050156A1 (es) 2005-04-27
PA8603601A1 (es) 2004-11-26

Similar Documents

Publication Publication Date Title
JP4676960B2 (ja) 第Ｘａ因子阻害剤としてのインドール誘導体
RU2299881C2 (ru) ИНДОЛ-2-КАРБОКСАМИДЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФАКТОРА Ха И/ИЛИ VIIa, ЛЕКАРСТВЕННОЕ СРЕДСТВО НА ИХ ОСНОВЕ И СПОСОБ ИХ ПОЛУЧЕНИЯ
JP4585448B2 (ja) 第Ｘａ因子阻害剤としてのピラゾール−誘導体
JP4861306B2 (ja) Ｘａ因子阻害剤としてのピロール誘導体
US20080280946A1 (en) Azaindole-Derivatives As Factor Xa Inhibitors
EP1479675A1 (en) Indazole-derivatives as factor Xa inhibitors
JP4608495B2 (ja) 第Ｘａ因子阻害剤としてのトリアゾール誘導体
JP4658940B2 (ja) 第Ｘａ因子阻害剤としてのベンゾイミダゾール誘導体
JP4733642B2 (ja) 第Ｘａ因子阻害剤としてのアザインドール−誘導体
HK1089174B (en) Benzimidazole-derivatives as factor xa inhibitors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070501

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070501

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100819

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101201

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110104

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110128

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140204

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees